We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.47B
AUM Growth
+$23.6M
Cap. Flow
+$98.4M
Cap. Flow %
3.98%
Top 10 Hldgs %
53.52%
Holding
129
New
25
Increased
23
Reduced
34
Closed
26

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$125M
2
Z icon
Zillow
Z
+$35.8M
3
UBER icon
Uber
UBER
+$21.2M
4
CYCN icon
Cyclerion Therapeutics
CYCN
+$19.3M
5
HOOK
HOOKIPA Pharma
HOOK
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$48.8M
2
IFRX icon
InflaRx
IFRX
+$31.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$11M
4
WVE icon
Wave Life Sciences
WVE
+$9.71M
5
VICI icon
VICI Properties
VICI
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 63.4%
2 Consumer Discretionary 15.74%
3 Technology 4.81%
4 Communication Services 1.88%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$1.04B
$379M 15.32%
60,240,864
– –
WW
2
DELISTED
WW International
WW
$283M 11.45%
14,818,300
– –
AVTR icon
3
Avantor
AVTR
$8.48B
$134M 5.4%
+7,000,000
New +$125M
BMY icon
4
CALL
Bristol-Myers Squibb
BMY
$130B
$102M 4.13%
2,250,000
+1,600,000
+246% +$74.5M
ONC
5
BeOne Medicines Ltd
ONC
$34.3B
$80.6M 3.26%
650,000
+50,000
+8% +$6.35M
BABA icon
6
Alibaba
BABA
$276B
$76.3M 3.08%
450,000
+38,000
+9% +$6.56M
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$70.7M 2.86%
750,000
-100,000
-12% -$8.25M
NVDA icon
8
NVIDIA
NVDA
$4.77T
$69M 2.79%
16,800,000
– –
MRNA icon
9
Moderna
MRNA
$22.1B
$67.4M 2.73%
4,606,298
-400,000
-8% -$8.59M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$61.6M 2.49%
1,500,000
-150,000
-9% -$6.21M
Z icon
11
Zillow
Z
$7.7B
$46.4M 1.88%
1,000,000
+900,000
+900% +$35.8M
RUBY
12
DELISTED
Rubius Therapeutics, Inc
RUBY
$44.6M 1.8%
2,833,791
-75,000
-3% -$1.21M
GM icon
13
CALL
General Motors
GM
$81.7B
$38.5M 1.56%
1,000,000
– –
SRRK icon
14
Scholar Rock
SRRK
$5.92B
$37.2M 1.5%
2,346,040
– –
MDCO
15
DELISTED
Medicines Co
MDCO
$36.5M 1.48%
1,000,000
+300,000
+43% +$9.79M
GOSS icon
16
Gossamer Bio
GOSS
$100M
$35.7M 1.44%
1,608,968
-50,000
-3% -$957K
BABA icon
17
CALL
Alibaba
BABA
$276B
$33.9M 1.37%
+200,000
New +$34.5M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$31.2M 1.26%
2,500,000
-100,000
-4% -$1.27M
ARGX icon
19
argenx
ARGX
$54.6B
$31.1M 1.26%
220,000
+20,000
+10% +$2.54M
FATE icon
20
Fate Therapeutics
FATE
$270M
$30.4M 1.23%
1,500,000
-300,000
-17% -$5.41M
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$38.5B
$29M 1.17%
400,000
-50,000
-11% -$3.84M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$27.5M 1.11%
150,000
+25,000
+20% +$4.27M
AGIO icon
23
Agios Pharmaceuticals
AGIO
$2.14B
$24.9M 1.01%
500,000
+100,000
+25% +$5.34M
NKTR icon
24
Nektar Therapeutics
NKTR
$2.39B
$24.9M 1.01%
46,667
-13,333
-22% -$6.69M
UBER icon
25
Uber
UBER
$144B
$23.2M 0.94%
+500,000
New +$21.2M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2019 Portfolio in Review

As of Q2 2019, Artal Group held 129 positions worth $2.47B, up 0.96% from $2.45B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Artal Group deployed $98.4M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Avantor: 7,000,000 shares worth $134M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 64% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $8.59M trimmed.

  • Artal Group's largest Q2 2019 buy was Avantor: 7,000,000 shares worth $134M.
  • Artal Group added most to Zillow in Q2 2019, an estimated $35.8M increase.
  • Artal Group's biggest Q2 2019 reduction was Moderna, cutting an estimated $8.59M.
  • Artal Group fully exited Array Biopharma Inc in Q2 2019, selling an estimated $48.8M.
  • Artal Group's ten largest holdings make up 54% of its $2.47B portfolio in Q2 2019.
  • Artal Group opened 25 new positions and closed 26 in Q2 2019.
  • Artal Group's portfolio value rose 0.96% quarter-over-quarter to $2.47B.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.